These medications include semaglutide (Ozempic for diabetes, Wegovy for obesity), liraglutide (Victoza for diabetes, Saxenda for obesity), dulaglutide (Trulicity, approved only for diabetes), and tirzepatide (Mounjaro for diabetes, Zepbound for obesity), which is a dual GLP-1/GIP receptor agonist
North Carolina State Health Plan Similarly, North Carolinas State Health Plan took action in January 2024 that took effect in April of last year, formally removing coverage for GLP-1 and GIPGLP-1 agonists when used for weightloss in obesity
"Generic drugs always have to go through the FDA's standards showing equivalence to the branded products
Nature 515:182184
Consult Healthcare Provider: If you frequently miss doses or are unsure about what to do after a missed dose, consult your healthcare provider for personalized advice
Heme oxygenase 1 is induced by mir-155 via reduced bach1 translation in endothelial cells